Patents Represented by Attorney Warrick E. Lee, Jr.
-
Patent number: 5539121Abstract: There is disclosed a novel formylating agent, 2-formylmercaptobenzothiazole.Type: GrantFiled: May 16, 1995Date of Patent: July 23, 1996Assignee: Schering CorporationInventors: Chou-Hong Tann, Tiruvettipuram K. Thiruvengadam, John S. Chiu, Cesar Colon, Michael D. Green
-
Patent number: 5512249Abstract: Apparatus for sterilizing a transfer conduit having(a) a source of steam connected to the transfer conduit,(b) a condensate conduit for draining steam condensate from the transfer conduit,(c) a valve in the condensate conduit having a valve body with an upstream portion and a downstream portion, the portions are separated by a rapidly opening flow control means, such as a diaphragm,(d) a temperature sensor in the upstream portion of the valve body, and(e) a temperature controller connected to the temperature sensor adapted to read the temperature in the upstream portion of the valve body and to open the valve when the temperature drops below a fixed set point and to close the valve when the temperature is above the fixed set point.A steam condensate drain control system and a steam condensate valve are also described and claimed.Type: GrantFiled: November 10, 1994Date of Patent: April 30, 1996Assignee: Schering CorporationInventor: Vijay Singh
-
Patent number: 5491091Abstract: A method is disclosed for disinfecting contact lenses with peroxide whereby the usual peroxide neutralization step is eliminated. This is accomplished by carrying out the disinfecting process at a hydrogen peroxide concentration of about 0.01 to less than 0.5% (w/v). In the preferred embodiment the peroxide is introduced into the system utilizing an effervescent tablet of an alkali metal perborate, percarbonate or persulfate, or urea peroxide.Type: GrantFiled: January 28, 1992Date of Patent: February 13, 1996Assignee: Schering CorporationInventors: Samuel Loshaek, Helmut Singer
-
Patent number: 5442047Abstract: An improved process for converting gentamicin B to isepamicin comprising forming 3,6'-di-N-formylgentamicin B, acylating the 1-amino group with an N-protected (S)-isoserine compound and removing all the blocking groups under conditions which result in high yields of isepamicin. A novel formylating agent, 2-formylmercaptobenzothiazole, and intermediate compounds are also disclosed.Type: GrantFiled: October 15, 1993Date of Patent: August 15, 1995Assignee: Schering CorporationInventors: Chou-Hong Tann, Tiruvettipuram K. Thiruvengadam, John S. Chiu, Cesar Colon, Michael D. Green
-
Patent number: 5414477Abstract: A colored contact lens having a very natural appearance is disclosed. The inventive lens has a non-opaque pupil section and iris section that is at least partially opaque and comprised of two portions. A first portion, generally located on the outside of the iris section, has a first shade. A second portion, generally located on the inside of the iris section has a second shade. A jagged border separates the two portions. A third iris section and second jagged border are also disclosed. In some embodiments portions of the iris section may be non-opaque.Type: GrantFiled: December 3, 1992Date of Patent: May 9, 1995Assignee: Wesley-Jessen CorporationInventor: Richard L. Jahnke
-
Patent number: 5316700Abstract: Process and apparatus for molding the front and rear surfaces of a contact lens in one step is disclosed. Two mold halves matable to form a contact-lens-shaped cavity and a cavity for excess lens forming material surrounding the cavity are provided. The improvement comprises providing the cavity for excess lens forming material with at least two openings and producing differential gas pressure across the openings to remove excess lens forming material.Type: GrantFiled: November 2, 1992Date of Patent: May 31, 1994Assignee: Wesley-Jessen CorporationInventors: Paul J. Soye, Samuel Loshaek
-
Patent number: 5302716Abstract: Disclosed are fused benzazepine compounds, pharmaceutical compositions including such compounds, methods of using such compounds, for example, in the treatment of psychoses and/or depression, and intermediates useful in the preparation of such compounds.Type: GrantFiled: November 6, 1990Date of Patent: April 12, 1994Assignee: Schering CorporationInventors: Joel G. Berger, Wei K. Chang, Elijah H. Gold, John W. Clader
-
Patent number: 5272010Abstract: Novel colored contact lens and methods for preparation thereof are described. Binding of a color coat to the lenses is accomplished by use of compounds containing the functional groups --CH.sub.2 --O--R.sup.1, wherein R.sup.1 is hydrogen or C.sub.1 to C.sub.16 alkyl, and said --CH.sub.2 --O--R.sup.1 groups are attached to a carbon atom that is part of an aromatic ring, or are attached to a nitrogen or oxygen atom.Type: GrantFiled: October 1, 1991Date of Patent: December 21, 1993Assignee: Wesley-Jessen CorporationInventor: Michael H. Quinn
-
Patent number: 5271874Abstract: A process for molding hydrophilic contact lenses comprising the steps of providing lens forming liquid comprising hydrophilic monomer mixed with solvent and polymerizing the liquid between two mold halves. The improvement comprises substantially removing the solvent by evaporation at temperature no higher than about 100 degrees C.Type: GrantFiled: November 4, 1992Date of Patent: December 21, 1993Assignee: Wesley-Jessen CorporationInventors: Clodia Osipo, Richard Jahnke
-
Patent number: 5247080Abstract: Disclosed herein are novel compounds of formula II ##STR1## and pharmaceutically acceptable salts thereof, wherein: Q represents H, halo or --OSO.sub.2 R" wherein R" is CH.sub.3, CF.sub.3, phenyl or tolyl;R.sup.3a represents H, alkyl, allyl, cyclopropylmethyl or COOR.sup.14 wherein R.sup.14 is alkyl, aryl, aralkyl or haloalkyl;R.sup.4 represents H, halo, alkyl, haloalkyl or alkoxy;R.sup.5a represents --OR.sup.10, --N(R.sup.9).sub.2, --O--C(R.sup.7).sub.2 .multidot.OCOR.sup.13, or alkoxy; wherein each R.sup.9 independently represents H, alkyl, alkoxy, alkoxyalkyl, aralkyl or aryl;R.sup.10 represents H, --COR.sup.9 or --CON(R.sup.9).sub.2 ; andR.sup.13 represents alkyl, aralkyl or aryl,with the proviso that R.sup.3a can not be hydrogen or alkyl when Q is hydrogen, R.sup.4 is hydrogen, and R.sup.5a is hydroxy.Compounds of formula II are useful intermediates for producing compounds having valuable pharmaceutical properties in treating psychosis, depression, pain and hypertension.Type: GrantFiled: February 21, 1991Date of Patent: September 21, 1993Assignee: Schering CorporationInventors: Joel G. Berger, Wei K. Chang, Marjorie Peters
-
Patent number: 5104814Abstract: The invention describes a kit and a method useful for analyzing the plasma concentration of an active neuroleptic drug known to have D-1 receptor antagonist properties utilizing labeled [-]trans 6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho-[2 ,1-b]-azepine.Type: GrantFiled: December 21, 1990Date of Patent: April 14, 1992Assignee: Schering CorporationInventors: Richard Chipkin, Robert D. McQuade
-
Patent number: 5091526Abstract: Biologically active, enantiomerically substantially pure intermediates of trans-hexahydro-benzo[d]naphtho[2,1-b]azepines are prepared.The present invention involves a process for preparing compounds of the general formula 3: ##STR1## wherein: R* is ##STR2## Each R.sup.1 is independently H or alkyl; Q is methylene, --O-- or --S--;m and n are independently variable and may each have a value of 0, 1 or 2, with the provisos that the sum of m and n is not greater than 3, that m may not equal zero when Q is --O-- or --S--, and that when Q is --CH.sub.2 --, m and n cannot both be zero;X is hydrogen, halo, alkyl, alkylthio, alkylsulfinyl, alkylsufonyl, hydroxy, alkoxy or trifluoromethyl;Y is hydrogen, hydroxy, alkoxy, --OC(O)NR.sup.2 R.sup.3, --OC(O)--R.sup.9, --N(R.sup.1).sub.2, --NHC(O)R.sup.1 or --OP(O)(OH)OR.sup.1,R.sup.2 and R.sup.3 are the same or different and each is hydrogen (provided that both are not hydrogen), alkyl, aralkyl, cycloalkyl, aryl, hydroxyalkyl, or alkoxyalkyl;in addition, when one of R.sup.Type: GrantFiled: January 8, 1991Date of Patent: February 25, 1992Assignee: Schering CorporationInventors: Joel G. Berger, John W. Clader
-
Patent number: 5062701Abstract: A contact lens comprising a corneal section, a vertical axis, and a shape adapted to maintain the lens at an intended orientation. The lens has either a visible horizontal line segment located in the corneal section perpendicular to the vertical axis and/or three visible radial line segments in the corneal section, the first of the line segments located on the vertical axis, and the second and third segments located on either side of the first segment such that the extensions of the segments would pass through a geometric center of the corneal section forming two 20.degree. angles. The lens is useful for measuring the rotation of an asymmetric lens. Methods for measuring lens rotation using the inventive lenses are also disclosed.Type: GrantFiled: November 16, 1990Date of Patent: November 5, 1991Assignee: Wesley-Jessen CorporationInventors: Martin J. Drazba, Michael L. Bellek, Samuel Dranoff, Paul Hahn
-
Patent number: 5035859Abstract: Contact lenses are disinfected by utilizing an N-alkyl-2-pyrrolidone as the microbicide. The efficacy of prior art microbicides such as chlorhexidene gluconate are enhanced by the addition of the pyrrolidones of this invention. The pyrrolidones suitable for use in the practice of this invention are the C.sub.8 -C.sub.20 N-alkyl-2-pyrrolidones. Preferably the alkyl moiety is octyl, decyl or dodecyl. The pyrrolidones can be utilized in solution or made available as a water soluble tablet.Type: GrantFiled: November 21, 1989Date of Patent: July 30, 1991Assignee: Schering CorporationInventors: Ben Gu, Kenneth E. Bliznik, Helmut K. Singer, Sharon M. Ward
-
Patent number: 5020898Abstract: A contact lens for correcting astigmatism. The front surface has a central optical zone and an outer carrier having two points of maximum thickness located at an oblique angle of about 110.degree. to 130.degree. as measured from the vertical axis of the lens. The anterior surface of the lens is symmetrical about its vertical axis. The carrier tapers from the points of maximum thickness to thin portions at the top and bottom of the lens.The rear surface of the lens has an outer spherical base curve zone, an inner toric zone, and an intermediate transition zone having thickness that gradually increase from the base curve zone to the toric zone. By making the radius of the base curve zone substantially equal to that of the toric zone's major meridian, a thinner, more comfortable lens is obtained.Type: GrantFiled: January 29, 1990Date of Patent: June 4, 1991Assignee: Schering CorporationInventor: Malcolm Townsley
-
Patent number: 5015639Abstract: Disclosed herein are novel 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are specified substituents.R.sup.1 is preferably --X.sup.6, --CHR.sup.7 R.sup.8, cycloalkyl, cycloalkenyl, ##STR2## or pyrrolyl where m is 1, R.sup.6 represents .dbd.H, phenyl, substituted phenyl, aralkyl, alkyl, cycloalkyl, haloalkyl or alkoxyalkyl, R.sup.7 represents H or alkyl preferably H, R.sup.8 represents cycloalkyl, cycloalkenyl, haloalkyl, alkoxyalkyl, alkenyl or alkynyl and R.sup.9 represents alkyl, aloxy or alkoxyalkyl.R.sup.2 preferably represents --H and R.sup.3 --CH.sub.3, and R.sup.4 is preferably halogen and R.sup.5 is preferably OH, OCO.R.sup.9 or --O(CR.sup.7).sub.2.OCO.R.sup.13 where R.sup.7 represents hydrogen, R.sup.9 is as defined above and R.sup.13 represents alkyl. The compounds of the formula I are indicated as being useful in the treatment of psychoses, depression and pain.Type: GrantFiled: March 13, 1989Date of Patent: May 14, 1991Assignee: Schering CorporationInventors: Joel G. Berger, Wei K. Chang, Marjorie Peters
-
Patent number: 4997771Abstract: The invention describes a method for determining the BZ-1 receptor activity of a test sample or a potential anxiolytic drug.Type: GrantFiled: April 27, 1987Date of Patent: March 5, 1991Assignee: Schering CorporationInventors: Allen Barnett, William Billard, Gordon Crosby, Jr., Louis Iorio, Martin Steinman
-
Patent number: 4996202Abstract: Substituted 8-amino-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines useful in treating mental disorders and which have activities of prolonged duration are disclosed. Methods for preparing these compounds and methods for their use are also described.Type: GrantFiled: October 17, 1985Date of Patent: February 26, 1991Assignee: Schering CorporationInventors: Joel G. Berger, Wei K. Chang, Elijah H. Gold, Arthur J. Elliott
-
Method for measuring the rotation of an assymetric contact lens and lenses for practicing the method
Patent number: 4976533Abstract: A contact lens comprising a corneal section, a vertical axis, and a shape adapted to maintain the lens at an intended orientation. The improvement comprises either a visible horizontal line segment located in the corneal section perpendicular to the vertical axis and/or three visible radial line segments in the corneal section, the first of the line segments located on the vertical axis, and the second and third segments located on either side of the first segment such that the extension of the segments would pass through a geometric center of the corneal section forming two 20.degree. angles. The lens is useful for measuring the rotation of an assymetric lens. Methods for measuring lens rotation using the invention lenses are also disclosed.Type: GrantFiled: June 7, 1988Date of Patent: December 11, 1990Assignee: Schering CorporationInventors: Paul Hahn, John Reynolds, Alan Tomlinson, Robert J. O'Meara, Martin Drazba -
Patent number: 4973586Abstract: Disclosed are fused benzazepine compounds, pharmaceutical compositions including such compounds, methods of using such compounds, for example, in the treatment of psychoses and/or depression, and intermediates useful in the preparation of such compounds.Type: GrantFiled: July 18, 1988Date of Patent: November 27, 1990Assignee: Schering CorporationInventors: Joel G. Berger, Wei K. Chang, Elijah H. Gold, John W. Clader